AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kodiak Sciences shares rise 6.15% premarket after announcing compelling new data for retinal disease treatments.
ByAinvest
Thursday, Aug 14, 2025 5:58 am ET1min read
Kodiak Sciences Inc. rose 6.15% in premarket trading, with the company announcing recent business highlights and financial results for the second quarter ended June 30, 2025. The company's CEO, Victor Perlroth, M.D., highlighted the transformative potential of their three late-stage clinical assets – tarcocimab, KSI-501, and KSI-101 – in retinal disease treatment. The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to retinal vein occlusion.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet